719 Stock Overview
Through its subsidiaries, develops, manufactures, and sells bulk pharmaceuticals, preparations, and chemical products in the People's Republic of China, the Americas, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 719 from our risk checks.
Shandong Xinhua Pharmaceutical Company Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$5.93 |
| 52 Week High | HK$8.05 |
| 52 Week Low | HK$4.80 |
| Beta | -0.022 |
| 11 Month Change | -3.42% |
| 3 Month Change | 12.31% |
| 1 Year Change | 0.34% |
| 33 Year Change | 48.25% |
| 5 Year Change | 58.98% |
| Change since IPO | 190.91% |
Recent News & Updates
Recent updates
Shandong Xinhua Pharmaceutical (HKG:719) Is Paying Out A Larger Dividend Than Last Year
Jun 28
Insufficient Growth At Shandong Xinhua Pharmaceutical Company Limited (HKG:719) Hampers Share Price
Jan 23Shandong Xinhua Pharmaceutical (HKG:719) Takes On Some Risk With Its Use Of Debt
Mar 07Is Shandong Xinhua Pharmaceutical (HKG:719) Using Too Much Debt?
Nov 18These 4 Measures Indicate That Shandong Xinhua Pharmaceutical (HKG:719) Is Using Debt Extensively
Jul 27Shandong Xinhua Pharmaceutical (HKG:719) Has Affirmed Its Dividend Of HK$0.18
Jul 04Estimating The Intrinsic Value Of Shandong Xinhua Pharmaceutical Company Limited (HKG:719)
Mar 09We Think Shandong Xinhua Pharmaceutical (HKG:719) Can Stay On Top Of Its Debt
Dec 21Does Shandong Xinhua Pharmaceutical (HKG:719) Deserve A Spot On Your Watchlist?
Apr 06What Kind Of Shareholders Own Shandong Xinhua Pharmaceutical Company Limited (HKG:719)?
Mar 19Is Shandong Xinhua Pharmaceutical (HKG:719) A Risky Investment?
Feb 26Are Shandong Xinhua Pharmaceutical's (HKG:719) Statutory Earnings A Good Guide To Its Underlying Profitability?
Feb 05
Shandong Xinhua Pharmaceutical (HKG:719) Share Prices Have Dropped 43% In The Last Three Years
Jan 18Is Shandong Xinhua Pharmaceutical Company Limited (HKG:719) A Smart Pick For Income Investors?
Dec 29Do Institutions Own Shandong Xinhua Pharmaceutical Company Limited (HKG:719) Shares?
Dec 14Is Shandong Xinhua Pharmaceutical (HKG:719) Using Too Much Debt?
Nov 26Shareholder Returns
| 719 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | 0.2% | 0.8% | 0.4% |
| 1Y | 0.3% | -7.5% | 12.0% |
Return vs Industry: 719 exceeded the Hong Kong Pharmaceuticals industry which returned -7.5% over the past year.
Return vs Market: 719 underperformed the Hong Kong Market which returned 12% over the past year.
Price Volatility
| 719 volatility | |
|---|---|
| 719 Average Weekly Movement | 9.4% |
| Pharmaceuticals Industry Average Movement | 6.8% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in HK Market | 18.9% |
| 10% least volatile stocks in HK Market | 4.3% |
Stable Share Price: 719 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 719's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1943 | 7,064 | Wenhui Xu | www.xhzy.com |
Shandong Xinhua Pharmaceutical Company Limited, through its subsidiaries, develops, manufactures, and sells bulk pharmaceuticals, preparations, and chemical products in the People's Republic of China, the Americas, Europe, and internationally. The company offers antipyretic and analgesic drugs; cardiovascular and cerebrovascular drugs; anti-infective drugs and central nervous drugs; and other drugs. It engages in the development of real estate business.
Shandong Xinhua Pharmaceutical Company Limited Fundamentals Summary
| 719 fundamental statistics | |
|---|---|
| Market cap | HK$9.86b |
| Earnings (TTM) | HK$482.15m |
| Revenue (TTM) | HK$8.96b |
8.4x
P/E Ratio0.5x
P/S RatioIs 719 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 719 income statement (TTM) | |
|---|---|
| Revenue | CN¥8.34b |
| Cost of Revenue | CN¥6.32b |
| Gross Profit | CN¥2.01b |
| Other Expenses | CN¥1.56b |
| Earnings | CN¥448.62m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.66 |
| Gross Margin | 24.15% |
| Net Profit Margin | 5.38% |
| Debt/Equity Ratio | 32.5% |
How did 719 perform over the long term?
See historical performance and comparison